Second-generation antipsychotics (SGAs) are preferred primarily because they cause fewer movement-related side effects than first-generation antipsychotics (FGAs). The American Psychiatric Association recommends SGAs as first-line medications for schizophrenia specifically because of this decreased risk. But the full picture is more nuanced: SGAs also offer modest advantages for certain hard-to-treat symptoms while introducing metabolic trade-offs that first-generation drugs largely don’t.
How They Work Differently in the Brain
Both generations of antipsychotics block dopamine receptors, which is the core mechanism that reduces hallucinations, delusions, and other psychotic symptoms. First-generation drugs do this bluntly, binding tightly to dopamine receptors across the brain. That tight, widespread blockade is effective against psychosis but also disrupts dopamine signaling in brain areas that control movement, which is where the notorious side effects come from.
Second-generation antipsychotics add a second layer of activity. They also bind to serotonin receptors, and the interplay between dopamine and serotonin binding changes how the drugs behave. Their therapeutic effects depend on a three-way interaction: stronger dopamine blocking increases potency, stronger binding at certain serotonin receptors enhances efficacy, but activity at a third serotonin receptor type actually reduces effectiveness. This more complex pharmacology appears to allow SGAs to control psychotic symptoms while being somewhat gentler on the brain’s movement circuits.
Lower Risk of Movement Disorders
The single biggest reason SGAs became the default choice is their reduced risk of extrapyramidal symptoms, the umbrella term for drug-induced movement problems like muscle stiffness, tremors, restlessness, and involuntary repetitive movements. These side effects range from uncomfortable to disabling, and they were a defining problem of first-generation treatment.
Tardive dyskinesia, the most feared of these effects, involves involuntary movements of the face, tongue, and limbs that can become permanent even after stopping the medication. Between 24% and 30% of patients on first-generation drugs develop it, with some studies reporting rates as high as 70% depending on the population. SGAs carry a meaningfully lower risk, though not zero. Earlier estimates suggested the risk with SGAs was about one-quarter that of FGAs, but more recent data from the large CATIE trial suggests the risk is closer to half to two-thirds that of older drugs (excluding clozapine, which has the lowest risk of all).
For akathisia, a deeply uncomfortable inner restlessness that makes it nearly impossible to sit still, the picture is less clear-cut. Roughly 25% of patients on first-generation drugs experience it, and some research suggests SGAs don’t actually improve on this much. The CATIE trial found no significant difference in akathisia rates between the antipsychotics tested, with both a second-generation and a first-generation drug causing it in about 7% of patients.
Modest Gains for Negative Symptoms and Cognition
Psychosis involves more than hallucinations and paranoia. Many people also experience “negative symptoms,” the loss of motivation, emotional expression, social engagement, and pleasure in everyday life. These symptoms are often more disabling than the dramatic ones, and first-generation drugs do little to help them.
SGAs perform better here, though the advantage is modest. In a meta-analysis of first-episode psychosis studies, pooled SGAs outperformed FGAs on negative symptoms with a small but statistically significant effect. Individual comparisons showed clearer benefits: olanzapine versus haloperidol, quetiapine versus haloperidol, and clozapine versus chlorpromazine all showed meaningful improvements in negative symptoms.
Cognitive impairment, including problems with memory, attention, and processing speed, is another area where SGAs show an edge. Pooled data from first-episode studies found that SGAs improved global cognition scores compared to FGAs over three to six months. This matters practically because cognitive difficulties often predict how well someone functions at work and in relationships, sometimes more than psychotic symptoms themselves.
People Stay on SGAs Longer
A medication only works if someone keeps taking it, and treatment discontinuation is one of the biggest challenges in managing psychosis. Side effects are the most common reason people stop, so the tolerability advantages of SGAs translate directly into better adherence. The same first-episode psychosis meta-analysis found that SGAs had significantly lower treatment discontinuation rates regardless of the reason for stopping.
The availability of long-acting injectable forms of SGAs has pushed adherence even further. In one large claims-based study, only 18.6% of people on long-acting injectable SGAs had a gap of 60 days or more in their medication, compared to 39.4% of those on oral antipsychotics. Rehospitalization rates were also lower: 15.8% versus 25.3%. These injectable formulations, given every few weeks instead of taken daily, remove the burden of remembering a daily pill and provide steadier drug levels.
The Metabolic Trade-Off
SGAs are not without serious drawbacks, and the most significant is metabolic disruption. Weight gain, rising blood sugar, and worsening cholesterol profiles are real concerns that vary considerably across specific SGAs.
Olanzapine is the clearest example. In a meta-analysis of studies across multiple psychiatric conditions, patients on olanzapine gained an average of 3.24 kg (about 7 pounds) more than those on placebo, with significant increases in triglycerides as well. This weight gain isn’t trivial: over months and years, it raises the risk of diabetes and cardiovascular disease. Quetiapine also raises triglycerides and total cholesterol while slightly lowering HDL (“good” cholesterol), though its effect on weight is less consistent across studies. Risperidone appears to be more metabolically neutral, with no statistically significant weight gain compared to placebo in pooled data.
This variation means that choosing an SGA involves balancing movement disorder risk against metabolic risk, and the calculus differs for each person. Someone with a family history of diabetes might do better on a metabolically friendlier option, while someone especially vulnerable to movement disorders might accept some metabolic monitoring in exchange for a drug with the lowest neurological risk.
Clozapine: The Exception That Proves the Rule
Clozapine, technically the first atypical antipsychotic ever developed, occupies a unique place. It is the only antipsychotic with clear evidence of superiority for treatment-resistant schizophrenia, defined as failing to respond to at least two adequate trials of other antipsychotics.
In the landmark study that established its reputation, 30% of treatment-resistant patients improved on clozapine after six weeks, compared to just 4% on a first-generation drug. Later studies pushed response rates even higher: one found that 50% of treatment-resistant patients responded. A meta-analysis of 31 trials confirmed that clozapine was more effective than conventional antipsychotics in both treatment-resistant and non-resistant patients, and it was found to be superior in 79% of controlled trials comparing it to other antipsychotics.
Despite this, clozapine is reserved for treatment-resistant cases rather than used first-line. It carries a rare but serious risk of a dangerous drop in white blood cells, requiring regular blood monitoring. It also causes significant weight gain and sedation. But for the estimated one-third of schizophrenia patients who don’t respond adequately to other medications, clozapine remains the most effective option available.
Why SGAs Became the Default
The preference for SGAs comes down to a practical calculation. They control psychotic symptoms about as well as first-generation drugs, offer small but real improvements in negative symptoms and cognition, and carry a meaningfully lower risk of movement disorders that patients find intolerable. People stay on them longer as a result, which prevents relapse and rehospitalization. The metabolic side effects are a genuine concern but can be monitored and managed, and newer SGAs like aripiprazole and ziprasidone carry less metabolic burden than older ones like olanzapine.
First-generation antipsychotics haven’t disappeared. They remain useful for patients who respond well to them, who have trouble with SGA side effects, or in situations where long-acting injectable formulations of older drugs are the best adherence strategy. But for most people starting treatment for the first time, the balance of evidence favors starting with a second-generation agent.